搜索结果
靶点ID:TCMBANKGE004194
靶点别名:PCB
靶点描述:pyruvate carboxylase
染色体:11
染色体位置:11q13.2
靶点类型:protein-coding
HERB_ID:-
HGNC_Link:8636
OMIM_Link:608786
Ensembl_Link:ENSG00000173599
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN022090 | oxalaceticacid | C4H4O5 | 132.07 g/mol | C(C(=O)C(=O)O)C(=O)O | |
| TCMBANKIN034198 | acetic acid | AI3-02394; NSC132953; Azijnzuur [Dutch]; Acido acetico [Italian]; Essigsaeure [German]; InChI=1/C2H4O2/c1-2(3)4/h1H3,(H,3,4; Pyroligneous acid; CARBOXYMETHYL GROUP; Caswell No. 003; 45727_FLUKA; A8976_SIAL; A6283_SIAL; 64-19-7; BRN 0506007; 318590_ALDRICH; 45730_FLUKA; 77671-22-8; cellulose diacetate; Acetic acid solution, with more than 10% and less than 50% acid, by mass [UN2790] [Corrosive]; 9035-69-2; 49199_FLUKA; Cellulose diacetate [USAN]; Cellulose, diacetate; FEMA Number 2006; W200611_ALDRICH; CBM; 320099_SIAL; Methanecarboxylic acid; 45726_FLUKA; NCIOpen2_000682; Glacial acetic acid; Acetic acid (JP15/NF); ethanoic acid; 207004-55-5; Otic Tridesilon; 40209_RIEDEL; Acetic acid, propionic acid distillate; NSC406306; 537020_SIAL; 45725_FLUKA; WLN: QV1; LS-2535; Acetic acid, glacial; 27225_RIEDEL; Ethylic acid; AKOS006290339; 07692_FLUKA; ACY; NSC 132953; ACT; 33206_RIEDEL; EPA Pesticide Chemical Code 044001; 380121_SIAL; W200603_ALDRICH; Acetic acid, glacial (USP); ethoic acid; Acetic acid, glacial or acetic acid solution, >80% acid, by mass [UN2789] [Corrosive]; 34254_RIEDEL; 4-02-00-00094 (Beilstein Handbook Reference); 46928_SUPELCO; Acido acetico; C00033; Acetasol (TN); Acetic acid solution, not less than 50% but more than 80% acid, by mass [UN2790] [Corrosive]; Carboxylic acids, C2-3; CHEBI:15366; Acetic acid, of a concentration of more than 10 per cent, by weight, of acetic acid; 45732_FLUKA; Acetic acid [JAN]; Octowy kwas [Polish]; Essigsaeure; Vinegar acid; 242853_SIAL; Glacial acetic acid (JP15); 38050_RIEDEL; A9967_SIAL; LS-1541; 38051_RIEDEL; Kyselina octova [Czech]; ST5213882; Acetate standard for IC; 33209_RIEDEL; UN2790; 40273_RIEDEL; Azijnzuur; Acetic acid solution; Acetic acid (natural); D00010; LMFA01010002; 27218_RIEDEL; Acetic acid, aqueous solution; HSDB 40; 68475-71-8; 34255_RIEDEL; NCIOpen2_000659; 34256_RIEDEL; FEMA No. 2006; CCRIS 5952; Acide acetique; Acetic acid, diluted; Acetasol; Octowy kwas; 71251_FLUKA; 338826_SIAL; EINECS 200-580-7; 13669_FLUKA; Acide acetique [French]; CH3-COOH; 45754_FLUKA; 157090-22-7; Acetic acid, water solutions; UN2789 | C5H10O3 | 118.13 | CC(=O)NCCC1=CN(C2=C1C=C(C=C2)OC)C(=O)C3=CC=C(C=C3)Cl |
| TCMBANKIN057911 | se | selenium | H2Se | 78.97 g/mol | [Se] |
| TCMBANKIN057919 | 2(R)-(3,4-dimethoxy-phenyl)-propanel,3-diol-l-O-β-D-glucopyranoside | formic acid;fatty acids;FMT;saturated fatty acids;formicacid; methanol peroxide; Dioxirane-3-ol;251364_SIAL; 64-18-6; 27001_RIEDEL; HCOOH; Kyselina mravenci [Czech]; methoic acid; 06473_FLUKA; Spirit of formic acid; Formira; CBX; RCRA waste no. U123; Formylic acid; Methanoic acid; 09676_FLUKA; Formic acid (natural); C1 acid; CCRIS 6039; 49897_FLUKA; 7056-83-9; Kwas metaniowy [Polish]; Bilorin; Myrmicyl; RCRA waste number U123; Ameisensaeure [German]; F0507_SIAL; Collo-didax; EINECS 200-579-1; UN1779; C00058; Add-F; InChI=1/CH2O2/c2-1-3/h1H,(H,2,3; 33015_RIEDEL; 82069-14-5; H-COOH; Collo-bueglatt; LMFA01010040; 94318_FLUKA; AI3-24237; Wonderbond Hardener M 600L; HSDB 1646; Mierenzuur [Dutch]; formic acid; 06450_FLUKA; Sybest; Formic acid solution; FEMA No. 2487; Formisoton; CHEBI:30751; Ameisensaeure; 399388_SIAL; ST5214364; 8006-93-7; Ameisensaure; Formate standard for IC; CARBOXY GROUP; LS-1540; Methanoic acid monomer; Formic acid [UN1779] [Corrosive]; W248703_ALDRICH; Acide formique [French]; Aminic acid; Acido formico [Italian]; 06460_FLUKA; 15907-03-6; Hydrogen carboxylic acid; EPA Pesticide Chemical Code 214900; 56302_FLUKA | HCOOH or CH2O2 | 46.025 g/mol;46.03 | C(=O)O |
| TCMBANKIN057923 | glycin | Tocris-0219; G5417_SIGMA; WLN: Z1VQ; LS-218; 56-40-6; Glycosthene; G7126_SIGMA; Hgly; Glycine-UL-14C hydrochloride; EINECS 200-272-2; Padil; Polyglycine II; AB-131/40217813; Acido aminoacetico [INN-Spanish]; Glycine [INN]; G7403_SIGMA; CCRIS 5915; GLY (IUPAC abbrev); W328707_ALDRICH; Glycine-2-3H; G3649_SIGMA; InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5; Glycine iron sulphate (1:1); NSC 25936; P8791_SIGMA; Leimzucker; Gyn-Hydralin; D00011; Aminoessigsaeure; 50046_FLUKA; Acidum aminoaceticum [INN-Latin]; Aminoethanoic acid; aminoacetic acid; AI3-04085; 33242-26-1; H2N-CH2-COOH; C00037; G8898_SIGMA; Glyzin; G0398_SIGMA; Amitone; Hampshire glycine; Glycocoll; G5523_SIGMA; Acide aminoacetique [INN-French]; Glycine-carboxy-14C hydrochloride; Glicina [INN-Spanish]; Glycinum [INN-Latin]; Glykokoll; ST5213923; 15527_RIEDEL; 7490-95-1; NChemBio.2007.13-comp1; Glycine, non-medical; BPBio1_001222; Biomol-NT_000195; 57678-19-0; Glycolixir; 63183-41-5; 87867-94-5; HSDB 495; AIDS071643; FEMA No. 3287; CHEBI:15428; 33226_RIEDEL; Sucre de gelatine; 17829-66-2; 410225_SIAL; NCGC00024503-01; 2-Aminoacetic acid; Aminoazijnzuur; NSC25936; Glycine (JP15/USP); polyglycine; 52955-63-2; carbonocyanidic acid; 32817-15-5; 2-aminoethanoic acid; Aciport; L-Glycine; Glicoamin; 25718-94-9; Acetic acid, amino-; G8790_SIGMA; AIDS-071643; NCGC00024503-02; Glycine, homopolymer (VAN); glycine;CHEMBL451140; N'-[N-(2a,3b-Dihydroxy-12-oleanen-28-oyl)-L-alanyl]-glycine; 2-[[(2S)-2-[[(4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-10,11-dihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]amino]propanoyl]amino]acetic acid;GLY | C2H5NO2 | 75.07 g/mol | C(C(=O)O)N |
| TCMBANKIN058907 | Azeton | ACETONE; 673781_ALDRICH; Methyl ketone; Propanon; propan-2-one; C00207; W332615_ALDRICH; Pyroacetic acid; 40308_RIEDEL; 67-64-1; EPA Pesticide Chemical Code 004101; propanone; CHEBI:15347; dimethylcetone; ST5214392; HSDB 41; 414689_ALDRICH; Acetone [UN1090] [Flammable liquid]; 323772_ALDRICH; Chevron acetone; 320110_SIAL; c0556; 154598_SIAL; EINECS 200-662-2; Aceton [German, Dutch, Polish]; Dimethylketal; 00561_FLUKA; Dimethylketon; 34850_SIAL; 2-propanone; Acetone (TN); 179973_ALDRICH; Dimethylformaldehyde; dimethylketone; WLN: 1V1; Acetone (NF); ZINC00895111; RCRA waste number U002; 24201_RIEDEL; Aceton; RCRA waste no. U002; 179124_SIAL; 34480_RIEDEL; FEMA No. 3326; UN1090; Pyroacetic ether; Ketone, dimethyl-; 270725_ALDRICH; 534064_ALDRICH; 90872_FLUKA; Ketone, dimethyl; Caswell No. 004; 32201_RIEDEL; D02311; InChI=1/C3H6O/c1-3(2)4/h1-2H; Dimethyl ketone; AI3-01238; NCGC00091179-01; Dimethyl formaldehyde; 40289_RIEDEL; W332607_ALDRICH; Ketone propane; NSC135802; NSC 135802; .beta.-Ketopropane; beta-Ketopropane; 650501_ALDRICH; CCRIS 5953; Acetone (natural); 443638_SIAL; 439126_ALDRICH;acetone | C3H6O | 58.08 | CC(=O)C |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000023 | Skin and Connective Tissue Diseases; Immune System Diseases | Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI000054 | Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI000064 | Digestive System Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI000066 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI000891 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI001965 | Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI003248 | Nutritional and Metabolic Diseases; Endocrine System Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease | |
| TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI003500 | Cardiovascular Diseases | Abnormality of blood and blood-forming tissues | Disease or Syndrome | disease | |
| TCMBANKDI004086 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
| TCMBANKDI004360 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Mental Disorders | Abnormality of metabolism/homeostasis | Disease or Syndrome | phenotype | |
| TCMBANKDI005318 | Digestive System Diseases; Chemically-Induced Disorders | - | Disease or Syndrome | disease | |
| TCMBANKDI005800 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI007520 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | disease | |
| TCMBANKDI007753 | Nervous System Diseases; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI007832 | Cardiovascular Diseases | - | Disease or Syndrome | phenotype | |
| TCMBANKDI009099 | Nutritional and Metabolic Diseases; Endocrine System Diseases | - | Experimental Model of Disease | disease | |
| TCMBANKDI009231 | Pathological Conditions, Signs and Symptoms; Infections | Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI009912 | Pathological Conditions, Signs and Symptoms | Abnormality of metabolism/homeostasis | Sign or Symptom | phenotype | |
| TCMBANKDI010214 | - | - | Neoplastic Process | disease | |
| TCMBANKDI012151 | Respiratory Tract Diseases; Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI013347 | Pathological Conditions, Signs and Symptoms | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
| TCMBANKDI013628 | Neoplasms; Skin and Connective Tissue Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI013745 | Neoplasms; Respiratory Tract Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI015660 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hemic and Lymphatic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI018016 | Eye Diseases; Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases; Stomatognathic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI023751 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the musculature | Finding | phenotype | |
| TCMBANKDI024262 | - | - | Neoplastic Process | phenotype | |
| TCMBANKDI024293 | Neoplasms | Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI024535 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI024989 | Hemic and Lymphatic Diseases; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI026782 | Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI027040 | Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI027339 | Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | disease | |
| TCMBANKDI029054 | Mental Disorders | - | Mental or Behavioral Dysfunction | group | |
| TCMBANKDI030165 | Hemic and Lymphatic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI030204 | - | - | Neoplastic Process | disease | |
| TCMBANKDI031570 | - | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI031651 | Digestive System Diseases; Neoplasms | - | Neoplastic Process | disease |
滇IICP备16009434号-1 |
Dai SX Lab